Immunome Inc.
Business
Immunome Inc. is a biotechnology company developing first-in-class and best-in-class targeted oncology therapies, with expertise in antibody-drug conjugates (ADCs) and other cancer treatments. The company's pipeline includes varegacestat (a gamma secretase inhibitor for desmoid tumors with Phase 3 data), IM-1021 (a ROR1-targeting ADC in Phase 1 trials), and IM-3050 (a FAP-targeted radioligand therapy in Phase 1), along with three preclinical solid-tumor ADCs. Immunome operates globally with commercial rights to varegacestat and intends to build internal commercial infrastructure in the U.S. and Europe while exploring partnerships in other markets.
Summary from 10-K filed 2026-03-03
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration revenue | 7 | 9 | 14 | — | — | |
| In-process research and development | 10 | 152 | 81 | — | — | |
| Research and development | 177 | 130 | 23 | 23 | 14 | |
| General and administrative | 44 | 33 | 20 | 14 | 11 | |
| Total operating expenses | 231 | 315 | 124 | 37 | 25 | |
| Loss from operations | −224 | −306 | −110 | −37 | −25 | |
| Interest income | 12 | 13 | 3 | 5,000 | −10,000 | |
| Net loss | −212 | −293 | −107 | −37 | −25 | |
| Net loss per share, basic | −2.43 | −5 | −5.38 | −3.09 | −2.14 | |
| Net loss per share, diluted | −2.43 | −5 | −5.38 | −3.09 | −2.14 | |
| Weighted-average shares outstanding, basic | 87 | 59 | 20 | 12 | 12 | |
| Weighted-average shares outstanding, diluted | 87 | 59 | 20 | 12 | 12 | |
| Net loss | −212 | −293 | −107 | −38 | −25 | |
| Unrealized (loss) gain on marketable securities | −57,000 | 35,000 | — | — | — | |
| Comprehensive loss | −212 | −293 | −107 | −38 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 654 | 143 | 99 | 20 | 49 | |
| Marketable securities | 0 | 74 | 39 | — | — | |
| Prepaid expenses and other current assets | 7 | 4 | 7 | 2 | 7 | |
| Total current assets | 661 | 221 | 145 | 23 | 57 | |
| Property and equipment, net | 15 | 10 | 2 | 681,000 | 855,000 | |
| Operating right-of-use assets | 3 | 4 | 2 | 284,000 | 500,000 | |
| Restricted cash | 200,000 | 100,000 | 100,000 | 100,000 | 100,000 | |
| Other long-term assets | 5 | 4 | 100,000 | — | — | |
| Total assets | 683 | 240 | 149 | 24 | 58 | |
| Accounts payable | 3 | 14 | 3 | 2 | 3 | |
| Accrued expenses and other current liabilities | 42 | 33 | 8 | 5 | 7 | |
| Deferred revenue, current | 0 | 7 | 10 | — | — | |
| Total current liabilities | 45 | 54 | 22 | 7 | 10 | |
| Operating lease liabilities, net of current portion | 4 | 5 | 1 | — | — | |
| Total liabilities | 49 | 59 | 29 | 7 | 10 | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2025 and 2024 | — | — | — | — | — | |
| Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2025 and 2024; 113,133,199 and 64,460,829 shares issued and outstanding at December 31, 2025 and 2024, respectively | 11,000 | 6,000 | 4,000 | 1,000 | 1,000 | |
| Additional paid-in capital | 1,362 | 697 | 343 | 133 | 127 | |
| Accumulated other comprehensive income | 0 | 57,000 | 22,000 | — | — | |
| Accumulated deficit | −728 | −516 | −223 | −116 | −79 | |
| Total stockholders' equity | 634 | 181 | 120 | 17 | 48 | |
| Total liabilities and stockholders' equity | 683 | 240 | 149 | 24 | 58 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −212 | −293 | −107 | −37 | −25 | |
| Depreciation and amortization | 3 | 2 | 500,000 | 400,000 | 800,000 | |
| Amortization of right-of-use asset | 489,000 | 535,000 | 271,000 | 209,000 | — | |
| Accretion of discounts on marketable securities | −3 | −3 | −512,000 | — | — | |
| Share-based compensation expense | 26 | 16 | 6 | 5 | 3 | |
| Loss on disposal of property and equipment | 896,000 | 0 | — | — | — | |
| Charge for purchase of in-process research and development assets, including upon achievement of milestones | 10 | 152 | — | — | — | |
| Prepaid expenses and other assets | −3 | 906,000 | −4 | 5 | −4 | |
| Accounts payable | −9 | 10 | −608,000 | −677,000 | 2 | |
| Accrued expenses and other current liabilities | 5 | 14 | 614,000 | −2 | 5 | |
| Deferred revenue | −7 | −9 | 16 | — | — | |
| Operating lease liabilities | −166,000 | −67,000 | 153,000 | — | — | |
| Net cash used in operating activities | −191 | −111 | −8 | −29 | −18 | |
| Maturities of marketable securities | 200 | 155 | — | — | — | |
| Purchases of marketable securities | −123 | −187 | −39 | — | — | |
| Purchases of property and equipment | −10 | −7 | −831,000 | −248,000 | −79,000 | |
| Purchases of in-process research and development assets | −6 | −46 | — | — | — | |
| Net cash provided by (used in) investing activities | 61 | −85 | −30 | −248,000 | −79,000 | |
| Proceeds from public offerings | 633 | 230 | — | — | — | |
| Proceeds from issuance of common stock under ATM | 46 | 20 | 34,000 | — | 1 | |
| Payment of offering costs | −39 | −15 | −9 | — | −222,000 | |
| Proceeds from exercise of stock options | 913,000 | 2 | 371,000 | 32,000 | 99,000 | |
| Proceeds from exercise of common stock warrants | 0 | 4 | — | — | — | |
| Net cash provided by financing activities | 640 | 241 | 116 | 32,000 | 28 | |
| Net increase in cash and cash equivalents and restricted cash | 510 | 45 | 78 | −29 | 9 | |
| Purchases of in-process research and development assets, including payments owed upon achievement of development milestones, in accounts payable and accrued expenses | 10 | 6 | — | — | — | |
| Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities | 1 | 3 | 372,000 | — | — | |
| Remeasurement of operating right-of-use asset and lease liability due to lease modifications | 811,000 | 2 | 226,000 | — | — | |
| Offering costs in accounts payable and accrued expenses and other current liabilities | 364,000 | 0 | — | — | — | |
| Issuance of common stock in exchange for in-process research and development assets | — | 98 | — | — | — | |
| Net liabilities assumed from purchases of in-process research and development assets | 0 | 2 | — | — | — | |
| Right-of-use assets obtained in exchange for operating lease liabilities | 0 | 1 | 1 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Immunome Inc.'s CIK number?
Immunome Inc.'s SEC CIK number is 0001472012 (1472012). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Immunome Inc.'s SEC filings?
All of Immunome Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Immunome Inc. last report earnings?
Immunome Inc. (IMNM) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-219367). This is Immunome Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Immunome Inc.'s most recent earnings 8-K?
Immunome Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-219367. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Immunome Inc.'s latest earnings 8-K →
Look up any company's CIK number →